These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8646703)

  • 21. [New techniques and methods in oncological biology: forward to molecular biopathology].
    Bidart JM; Assicot M
    Bull Cancer; 2001 Jan; 88(1):9-14. PubMed ID: 11182648
    [No Abstract]   [Full Text] [Related]  

  • 22. [Isolated tumor cells in primary malignant liver tumors].
    Tannapfel A; Geissler F; Witzigmann H; Wittekind C
    Zentralbl Chir; 2000; 125(7):602-5. PubMed ID: 10960969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Researchers exploring implications of minimal residual cancer.
    McBride G
    J Natl Cancer Inst; 2005 Nov; 97(22):1642-3. PubMed ID: 16288116
    [No Abstract]   [Full Text] [Related]  

  • 24. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
    Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
    Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies.
    Jilani I; Keating M; Day A; William W; Kantarjian H; O'brien S; Giles FJ; Albitar M
    Clin Lab Haematol; 2006 Oct; 28(5):325-31. PubMed ID: 16999724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follicular lymphoma: quantitation of minimal residual disease by PCR of the t(14;18) translocation.
    Darby A; Gribben JG
    Methods Mol Med; 2005; 115():315-31. PubMed ID: 15998976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Projects of the 6th European Framework Program].
    Thalmann G
    Urologe A; 2007 Sep; 46(9):1274-8. PubMed ID: 17665161
    [No Abstract]   [Full Text] [Related]  

  • 28. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
    Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M
    Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
    Hokland P; Ommen HB; Nyvold CG; Stentoft J; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
    Ugeskr Laeger; 2009 Jan; 171(4):232-5. PubMed ID: 19174038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical applications of molecular monitoring in leukemia.
    Maslak P
    Curr Hematol Rep; 2003 Jan; 2(1):43-8. PubMed ID: 12901153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.
    Cazzaniga G; Biondi A
    Haematologica; 2005 Mar; 90(3):382-90. PubMed ID: 15749670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The detection and significance of minimal residual disease in acute and chronic leukemia.
    Chung NG; Buxhofer-Ausch V; Radich JP
    Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methods for isolation and genetic analysis of circulating tumor DNA in patient plasma.
    Kawaguchi T; Holland WS; Gumerlock PH
    Methods Mol Med; 2003; 85():257-62. PubMed ID: 12710213
    [No Abstract]   [Full Text] [Related]  

  • 34. Chemotherapy alone may lead to a PCR negative stem cell harvest in transformed lymphoma refractory to rituximab.
    Cerny J; Slavickova A; Krepelova A; Trneny M; Klener P
    Haematologica; 2003 Mar; 88(3):ECR06. PubMed ID: 12651284
    [No Abstract]   [Full Text] [Related]  

  • 35. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.
    Sausville JE; Salloum RG; Sorbara L; Kingma DW; Raffeld M; Kreitman RJ; Imus PD; Venzon D; Stetler-Stevenson M
    Am J Clin Pathol; 2003 Feb; 119(2):213-7. PubMed ID: 12579991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Detection of minimal residual leukemia using polymerase chain reaction method].
    Naoe T
    Rinsho Byori; 1996 Jun; 44(6):535-40. PubMed ID: 8752731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating cancer cells and their clinical applications.
    Diamandis EP; Pantel K; Scher HI; Terstappen L; Lianidou E
    Clin Chem; 2011 Nov; 57(11):1478-84. PubMed ID: 21586640
    [No Abstract]   [Full Text] [Related]  

  • 38. [Biologic detection methods in the comparison of circulating tumor cells and micrometastases].
    Dombóvári Z; Molnár B; Bocsi J; Láng I; Papik K; Fehér J; Tulassay Z
    Orv Hetil; 1998 Jul; 139(30):1793-7. PubMed ID: 9718947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Childhood acute leukemia: current status and future perspectives in MRD-based therapy].
    Tsurusawa M
    Rinsho Ketsueki; 2005 Feb; 46(2):109-20. PubMed ID: 16447704
    [No Abstract]   [Full Text] [Related]  

  • 40. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
    Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
    Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.